bioTheranostics Gets $32M For Cancer Diagnostics

San Diego-based bioTheranostics announced this morning that it has raised $32M in a funding round, and a spinout from parent company bioMerieux. The molecular diagnostics company said the funding was led by MVM Life Science Partners, and also included the Canepa Advanced Healthcare Fund and HealthQuest Capital. The company, led by President and CEO Nicolas Barthelemy, said the funding will go towards growing its commercial presence and expanding its clinical development programs. bioTheranostics develops a molecular diagnostics test for cancer, and is currently focused on breast cancer diagnosis. More information »